Summary of LENZ Therapeutics Conference Call Company Overview - **Company**: LENZ Therapeutics (NasdaqGS:LENZ) - **Product**: Eye drop for treating presbyopia, named VIZZ - **Launch Timeline**: Product approved in August and launched in October 2025 Industry Context - **Market Size**: Approximately 120 million presbyopes in the U.S. [18] - **Competitive Landscape**: - LENZ is the only company with aceclidine as an active ingredient - Competitors include AbbVie's VUITY (pilocarpine-based) and Qlosi (low-dose pilocarpine), both of which have shown limited efficacy [12][13] - VUITY had a 25% effectiveness rate, with only 1 in 4 patients noticing an effect [12] - VUITY's sales force has significantly reduced, indicating market struggles [13] Product Efficacy - **Mechanism of Action**: Aceclidine stimulates the iris sphincter to create a smaller pupil, enhancing near vision without affecting distance vision [9][10] - **Clinical Trial Results**: - 71% of patients experienced significant near vision improvement after 10 hours of use [8] - The product is designed to provide near vision improvement for the majority of the day [8] Launch Insights - **Initial Feedback**: Positive reception from both doctors and patients, with high awareness and willingness to prescribe [30][31] - **Refill Rates**: Early indications show encouraging refill rates, suggesting product stickiness [29] - **Sampling Strategy**: A robust sampling strategy is in place, allowing patients to try the product before committing to a prescription [29][40] Sales and Marketing Strategy - **Sales Force Expansion**: Plans to increase the sales force to 117 representatives to enhance market penetration [34] - **Target Audience**: 80% of prescriptions are written by optometrists, with the remaining 20% by ophthalmologists [46] - **Geographic Focus**: Strong sales in states like Florida, California, New York, and Texas [49] Safety and Side Effects - **Adverse Events**: Minimal reports of side effects such as headaches, redness, or dimness, with most effects being short-lived [85][90] - **Retinal Issues**: LENZ has reported only one case of retinal tear, compared to 34 reported by VUITY, indicating a safer profile [91][96] Market Expectations - **Sales Projections**: Consensus estimates for quarterly sales are around $2 million, with annual projections between $35-$40 million [129][130] - **Investor Sentiment**: There is impatience in the investment community regarding script data, but the company emphasizes the importance of building a market and establishing a solid foundation [168][170] Future Plans - **Direct-to-Consumer Campaign**: A DTC campaign has been initiated to increase awareness and drive prescriptions, with early signs of increased web traffic and interest [146][148] - **International Expansion**: The company is pursuing partnerships for international commercialization, with recent filings in Europe [173] Conclusion - LENZ Therapeutics is positioned uniquely in the presbyopia market with a product that shows promising efficacy and safety. The company is focused on expanding its market presence through strategic sales efforts and marketing campaigns while addressing investor concerns about growth and market penetration.

Summary of LENZ Therapeutics FY Conference Call Company Overview - **Company**: LENZ Therapeutics (NasdaqGS:LENZ) - **Industry**: Ophthalmology, specifically focusing on presbyopia treatment - **Recent Development**: Recently approved therapy for presbyopia, an age-related vision condition affecting near vision [1][2] Core Points and Arguments Product Differentiation - LENZ Therapeutics developed an ophthalmic drop using aceclidine, a previously marketed glaucoma product, to treat presbyopia non-invasively [4][3] - The product aims to create a pin-hole pupil effect, improving near vision for patients aged 45 and older [6][7] - The target product profile includes a once-daily application that provides rapid and long-lasting effects, with 93% of patients achieving at least 20/40 vision [10][12] Clinical Data - Phase 3 CLARITY trials showed: - 71% of patients achieved a three-line improvement in near vision within 30 minutes [12] - 95% of participants achieved at least two lines of near vision improvement [11] - 93% of patients reached 20/40 vision or better within an hour, with 70% maintaining this level after 10 hours [10][13] Market Opportunity - There are approximately 128 million presbyopia patients in the U.S., with a significant portion expressing interest in an ophthalmic drop solution [7][19] - The company targets specific segments, including contact lens wearers, LASIK patients, and active aging individuals, each exceeding 10 million potential users [20][21][22] Commercial Strategy - The commercial strategy consists of three pillars: 1. **Doctors to recommend**: An 88-person sales force targeting 13,000 doctors, with a focus on optometry [14][16] 2. **Consumers to request**: A direct-to-consumer (DTC) campaign launching in Q1 2026 [15][44] 3. **Seamless access**: Ensuring easy access to the product through e-pharmacy and retail channels [15] Pricing Strategy - The product is priced at $79 per month, aligning with competitor VUITY, which had a successful launch at the same price point [24][25] - A three-month pack is available for $198, offering a lower monthly cost [25] Lessons from Competitors - The company learned from VUITY's experience, which had a strong initial launch but failed to maintain momentum due to efficacy issues [27][28] - LENZ Therapeutics emphasizes the importance of delivering on the product's promise of immediate results to avoid consumer disappointment [28][29] Key Performance Indicators (KPIs) - Metrics to track post-launch include: - Number of doctors prescribing the product - Frequency of prescriptions (refill rates) - Consumer engagement through the vis.com website [36][50] Additional Insights - The company has received positive anecdotal feedback from both patients and doctors regarding the product's efficacy and ease of use [40][41] - The marketing campaign will feature a celebrity endorsement and target platforms like Facebook, Instagram, and YouTube [46][48] Conclusion LENZ Therapeutics is positioned to capture a significant share of the presbyopia treatment market with its innovative ophthalmic drop, backed by strong clinical data and a comprehensive commercial strategy. The focus on immediate efficacy and targeted marketing will be crucial for the product's success in a competitive landscape.

Summary of LENZ Therapeutics Conference Call Company Overview - **Company**: LENZ Therapeutics - **Product**: Viz, an eye drop treatment for presbyopia, which is the age-related loss of near vision [4][5] Key Points and Arguments FDA Approval and Product Launch - LENZ received FDA approval for Viz a week ahead of schedule, with the brand name revealed at that time [5] - The product is designed to restore near vision without affecting distance vision, allowing users to regain functionality throughout the workday [4][5] Market Opportunity - There are approximately **128 million presbyopes** in the U.S., representing a significant market potential [7] - The product is a self-pay solution, requiring a prescription from a doctor [7] Commercial Strategy - A three-pronged commercial strategy includes: 1. **Doctor Recommendations**: A sales force of **100 representatives** is targeting **15,000 doctors**, focusing primarily on optometrists [7][9] 2. **Direct-to-Consumer (DTC) Marketing**: Planned to launch in Q1 of the following year, aimed at motivating consumers frustrated with reading glasses [10][21] 3. **Seamless Patient Journey**: Simplifying the process from doctor visit to product delivery, including a five-day sample and easy ordering through e-pharmacy [12][20] Competitive Landscape - LENZ aims to differentiate Viz from competitors like VUITY, emphasizing that Viz is **three times more efficacious** and has a longer duration of effect [31][32] - The product is designed for a broad patient population, with high interest among users of contact lenses, those who have had LASIK, and the active aging demographic [24][25][26] Patient Usage Patterns - Clinical trial data indicates that **75%** of users expressed a desire to continue using the product, with expectations of **four to seven days of use per week** [27][28] - A conservative estimate suggests **five refills per year** per patient [28] Manufacturing and Logistics - The product's active pharmaceutical ingredient (API) is manufactured in the U.S. and filled in Germany, with a focus on maintaining a robust supply chain [44][45] - The product can be stored at room temperature for consumer convenience, although it should be refrigerated for longer-term storage [46][47] Future Growth and Expansion - LENZ plans to focus on the U.S. market initially, with potential expansions into international markets like Greater China and Canada, where similar branding and marketing strategies will be employed [57][59][60] - The company is open to future product expansion but is currently focused on the successful launch of Viz [73][74] Additional Important Information - The company is aware of the challenges faced by competitors and is taking a strategic approach to avoid pitfalls seen in previous product launches [14][29] - Feedback from doctors has been largely positive, with a low percentage expressing disinterest in the product [71][72] This summary encapsulates the key points discussed during the LENZ Therapeutics conference call, highlighting the company's strategic approach to launching Viz and its potential impact on the presbyopia treatment market.